Adeno-associated viral vector manufacturing: Keeping pace with accelerating clinical development

Human Gene Therapy

Volumn 22, Issue 8, 2011, Pages 913-914

  Wright, J Fraser ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR;

BACULOVIRUS; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SCREENING; GOOD MANUFACTURING PRACTICE; NOTE; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS PURIFICATION; VIRUS RECOMBINANT;

ANIMALS; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS;

EID: 80051993162     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.2514     Document Type: Note

References (3)

1. Mingozzi, F., and High, K.A. (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nat. Rev. Genet. 12, 341-355.
2. Urabe, M., Ding, C., and Kotin, R.M. (2002). Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 13, 1935-1943. (Pubitemid 35341035)
3. Wasilko, D.J., Lee, S.E., Stutzman-Engwall, K.J., et al. (2009). The titerless infected-cells preservation and scale-up (TIPS) method for large-scale production of NO-sensitive human soluble guanylate cyclase (sGC) from insect cells infected with recombinant baculovirus. Protein Expr. Purif. 65, 122-132.